Maxor selected by Insmed to be limited distribution provider of ARIKAYCE®

News provided by

Maxor National Pharmacy Services, LLC

Dec 04, 2018, 17:40 ET

AMARILLO, Texas, Dec. 4, 2018 /PRNewswire/ -- Maxor National Pharmacy Services, LLC, a specialty pharmacy leader in pulmonary rare disease management, announced today that its family of specialty pharmacies have been selected as limited distribution providers of ARIKAYCE^® (amikacin liposome inhalation suspension).

ARIKAYCE^® is an aminoglycoside antibacterial, recently approved by the U.S Food and Drug Administration for the treatment of Mycobacterium avium complex (MAC) lung disease in adults as a part of a combination antibacterial drug regimen in patients with limited to no treatment options. This is the first approved product under the FDA's Limited Population Antibacterial Drug and Accelerated Approval pathway.

ARIKAYCE^® is the latest addition to a growing number of limited distribution products available at Maxor's family of specialty pharmacies.

"We are excited to be named a national provider of ARIKAYCE^® and look forward to further expanding our services within the MAC lung disease community. There is a large unmet medical need for effective treatments for MAC lung disease and we are especially thrilled to help this new product reach and improve the lives of thousands of patients," said Mike Einodshofer, RPh, Chief Pharmacy Officer, Maxor.

About Maxor

Maxor's family of specialty pharmacies include IV Solutions and Pharmaceutical Specialties, LLC. A leader in rare and orphan disease management, Maxor integrates sophisticated clinical management strategies with a personalized high-touch approach to patient engagement. Maxor's pharmacies are licensed in all 50 states, and hold accreditations from URAC, ACHC, and The Joint Commission.

SOURCE Maxor National Pharmacy Services, LLC